Who
Joseph P. Slattery
Director
Company insider
Files Form 4 as: Director, ImageneBio; Director, CVRx; Director, Replimune Group; Director, Morphic Holding; EVP and CFO, Transenterix; Executive V.P. and CFO, Baxano Surgical; Director, Micromet; Chief Financial Officer & SVP, Digene.
In numbers
- Trades disclosed
- 303
- Buys
- 22
- Sells
- 25
- Bought
- $930K
- Sold
- $11.2M
- Companies
- 8
- Companies where not an officer
- 5
- First trade
- 27 Jan 2006
- Last trade
- 16 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 18 Jun 2026 | IMA ImageneBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —15,600 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | IMA ImageneBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —15,600 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | CVRX CVRxMedical Devices | SEC FORM 4 Code A | —8,720 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | CVRX CVRxoption or derivative · Medical Devices | SEC FORM 4 Code A | —11,182 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | CVRX CVRxoption or derivative · Medical Devices | SEC FORM 4 Code A | —11,182 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | CVRX CVRxMedical Devices | SEC FORM 4 Code A | —8,720 at $0.00 | filing |
| 1 Apr 2026filed 7 Apr 2026 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,500 at $0.00 | filing |
| 1 Apr 2026filed 7 Apr 2026 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,500 at $0.00 | filing |
| 24 Dec 2025filed 29 Dec 2025 | IMA ImageneBioBiotechnology | SEC FORM 4 Bought | $96K16,000 at $5.99 | filing |
| 18 Dec 2025filed 22 Dec 2025 | IMA ImageneBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —31,200 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | CVRX CVRxoption or derivative · Medical Devices | SEC FORM 4 Code A | —19,554 at $0.00 | filing |
| 1 Apr 2025filed 3 Apr 2025 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 16 Aug 2024filed 20 Aug 2024 | Morphic Holdingoption or derivative | SEC FORM 4 Code D | —24,000 | filing |
| 16 Aug 2024filed 20 Aug 2024 | Morphic Holdingoption or derivative | SEC FORM 4 Code D | —12,000 | filing |
| 16 Aug 2024filed 20 Aug 2024 | Morphic Holdingoption or derivative | SEC FORM 4 Code D | —9,615 | filing |
| 16 Aug 2024filed 20 Aug 2024 | Morphic Holdingoption or derivative | SEC FORM 4 Code D | —17,550 | filing |
| 16 Aug 2024filed 20 Aug 2024 | Morphic Holdingoption or derivative | SEC FORM 4 Code D | —12,535 | filing |
| 16 Aug 2024filed 20 Aug 2024 | Morphic Holdingoption or derivative | SEC FORM 4 Code D | —23,168 | filing |
| 16 Aug 2024filed 20 Aug 2024 | Morphic Holding | SEC FORM 4 Code D | —9,066 | filing |
| 15 Aug 2024filed 15 Aug 2024 | CVRX CVRxMedical Devices | SEC FORM 4 Bought | $24K3,000 at $8.10 | filing |
News
Critical Comparison: ImageneBio (NASDAQ:IMA) & AC Immune (NASDAQ:ACIU)IMA · tickerreport.com · 19 Oct 2026ImageneBio (NASDAQ:IMA) versus Agenus (NASDAQ:AGEN) Financial SurveyIMA · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name Joseph P. Slattery; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.